Concord Medical closes acquisition of additional ownership interest in MD Anderson Proton Therapy Center

Concord Medical Services Holdings Limited ("Concord Medical," or the "Company") (NYSE: CCM), a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced that it has closed the acquisition of additional ownership interest of The University of Texas MD Anderson Cancer Center ("MD Anderson") Proton Therapy Center ("MD Anderson Proton Therapy Center"). The purchase price of the all-cash transaction was not disclosed. Concord Medical purchased the interest from an existing owner of the general partner, and the transaction does not affect MD Anderson's majority ownership in the Proton Therapy Center.

With the closing, Concord Medical is now the controlling shareholder of PTC-Houston Management, LP (PTCHM), the general partner of the center, and will consolidate its financial results beginning in Q3 of 2015. Concord Medical will remain the second largest shareholder of the MD Anderson Proton Therapy Center, with MD Anderson retaining its 51% majority interest. PTCHM has appointed Concord Medical's Adam Sun as Chairman of its Board of Directors. In addition, Concord will appoint one new academic member to the center's Advisory Committee.

Concord Medical acquired 19.98% of indirect ownership of MD Anderson Proton Therapy Center in December 2012.

"We're very excited to strengthen our partnership with MD Anderson Proton Therapy Center, one of the leading proton treatment centers in the world," says Dr. Jianyu Yang, Concord Medical Chairman and CEO. "We will continue to directly assist PTCHM and MD Anderson to expand its business and market reach in China, the fastest growing healthcare market in the world."

"China has the largest potential market for advancing proton beam therapy treatment to patients in need throughout the country. Concord Medical plans to build and operate multiple proton centers in China. This transaction will help Concord Medical consolidate its leadership position in the radiotherapy industry and build an exchange platform for academics and clinical expertise with physicians in China, the U.S. and abroad."

Dan Fontaine, Executive Chief of Staff at MD Anderson says, "We welcome this opportunity to expand our strong relationship with Concord Medical. Together, we will continue build upon the clinical expertise and high quality programs provided by our faculty and staff which have positioned our Proton Therapy Center as the leader in the field of radiation oncology."

"Concord Medical has been a valuable & strategic partner with PTCH since 2012," said John Styles, Jr., CEO and Manager of the center. "We look forward to working closely with Concord Medical's team to expand our presence and benefit more patients in China. Our partnership is dedicated to assisting MD Anderson in achieving its goal of 'Making Cancer History'."

Opened in 2006, MD Anderson Proton Therapy Center was the fourth proton treatment center in the U.S. Since it's opening, the center has treated more than 6,000 patients, accounting for 15% of the total number of patients who received proton treatment nationally.

Wilson Sonsini Goodrich & Rosati represented Concord Medical as its legal advisor in the acquisition.


Concord Medical Services Holdings Limited


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Men with inherited gene mutation have high risk of aggressive prostate cancer